Tai, Y., Chow, A., Han, S., Coker, C., Ma, W., Gu, Y., Estrada Navarro, V., Kandpal, M., Hibshoosh, H., Kalinsky, K., Manova-Todorova, K., Safonov, A., Walsh, E. M., Robson, M., Norton, L., Baer, R., Merghoub, T., Biswas, A. K., & Acharyya, S. (2024). FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer. EMBO Molecular Medicine, 16(8), 1957–1980. https://doi.org/10.1038/s44321-024-00094-2

Boila, L. D., Ghosh, S., Bandyopadhyay, S. K., Jin, L., Murison, A., Zeng, A. G. X., Shaikh, W., Bhowmik, S., Muddineni, S. S. N. A., Biswas, M., Sinha, S., Chatterjee, S. S., Mbong, N., Gan, O. I., Bose, A., Chakraborty, S., Arruda, A., Kennedy, J. A., Mitchell, A., … Sengupta, A. (2023). KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition. Leukemia, 37(4), 751–764. https://doi.org/10.1038/s41375-023-01833-z

Langelier, M.-F., Lin, X., Zha, S., & Pascal, J. M. (2023). Clinical PARP inhibitors allosterically induce PARP2 retention on DNA. Science Advances, 9(12). https://doi.org/10.1126/sciadv.adf7175

Zhang, H., Lin, X., & Zha, S. (2022). Revisiting PARP2 and PARP1 trapping through quantitative live-cell imaging. Biochemical Society Transactions, 50(4), 1169–1177. https://doi.org/10.1042/bst20220366

Lin, X., Jiang, W., Rudolph, J., Lee, B. J., Luger, K., & Zha, S. (2022). PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites. Nucleic Acids Research, 50(7), 3958–3973. https://doi.org/10.1093/nar/gkac188